chevron_leftBack
As of 15 June 2026, Guizhou Xinbang Pharmaceutical Co., Ltd. has a market cap of $923.57M USD, ranking #11154 globally and #3195 in China.
It ranks #1008 in the Healthcare sector, and #376 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$923.57MUSD
6.26B CNY
Enterprise Value
$860.44MUSD
5.82B CNY
Revenue (TTM)
$829.33MUSD
5.62B CNY
EBITDA (TTM)
$79.82MUSD
540.18M CNY
Net Income (TTM)
$17.75MUSD
120.29M CNY
EBITDA Margin
9.6%
Profit Margin
2.1%
PE Ratio
52.1
PS Ratio
1.1
PB Ratio
0.9
EV/EBITDA
10.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Lingzhong Kong
open_in_new
Employees
5,059
Founded
1995
Website
xinbang.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.1% | 5.7% | 3.7% | -0.9% | -13% | -1.8% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
002390
贵州信邦制药股份有限公司 Class A
ISIN: CNE100000NG5
Shares Out.:
Shares Outstanding:
1.78B1
Shares Float:
963.897M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
3.37 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Guizhou Xinbang Pharmaceutical Co., Ltd.
Guizhou Xinbang Pharmaceutical Co., Ltd. manufactures and sells traditional Chinese medicine and other pharmaceutical products in China and internationally. The company cardiovascular and cerebrovascular, digestive system, endocrine, tumors and immunomodulatory drugs, blood system drugs, rheumatism and rheumatoid arthritis, urinary system, antipyretic and analgesic, cold medicine, gynecological medications, and anti-infective drugs. It also provides medical services. The company was founded in 1995 and is headquartered in Guiyang, China.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SSE: 600276
|
$53.85B
6K%
364.89B CNY
|
44.9
|
|
SSE: 603259
|
$49.64B
5K%
336.36B CNY
|
17.2
|
|
SHEK: 3692
|
$28.52B
3K%
223.48B HKD
|
35.7
|
|
SHEK: 1801
|
$18.8B
2K%
147.32B HKD
|
162.3
|
|
SSE: 688506
|
$16.51B
2K%
111.89B CNY
|
-
|
|
SHEK: 9926
|
$16.01B
2K%
125.46B HKD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
82K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
59K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
39K%
|
97.4
|
|
SIX: RO
|
$321.52B
35K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
31K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
30K%
218.9B CHF
|
20.5
|
chevron_leftBack